A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

NCT03635892 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
Unclassified Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Fumarate Hydratase Deficient Renal Cell Carcinoma
Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Collecting Duct Renal Cell Carcinoma
Chromophobe Renal Cell Carcinoma

Interventions

DRUG: cabozantinib
DRUG: nivolumab

Sponsor

Memorial Sloan Kettering Cancer Center